Sep 05, 2017
Neil Grubert reviews the UK’s post-Brexit life sciences strategy, with a particular focus on the key area of market access.
Sep 04, 2017
As regulators lower evidentiary requirements for approval to speed development/review of new drugs for unmet medical needs, payers are demanding more data to justify price premiums. How can companies can navigate these complexities?
Aug 25, 2017
Pharmaceutical Executive
Experts assess the current pharma dealmaking landscape—one where, despite market headwinds, is still heavily influenced by factors under the buyer and seller’s control.
Aug 10, 2017
In the first of three blogs on how digital strategy and a “data culture” can help define and deliver value, David Ormesher focuses on Value Creation.
Jul 06, 2017
Big data has proven to be a valuable business asset, but using it to gain competitive advantage requires the right combination of strategy, technology and execution.
Jun 20, 2017
Most challenges boil down to two simple categories: "complicated" and "complex". Knowing how to categorize each problem is key to solving it, writes Steve Figman.
Jun 12, 2017
Pharmaceutical Executive
With the patient voice growing louder in all aspects of the drug development and commercialization journey, Pharm Exec examines some of the current industry thinking on the evolving pharma-patient relationship.
Jun 11, 2017
Jackie DeAngelis outlines three common mistakes that hinder access attainment when launching a new drug.
May 12, 2017
Pharmaceutical Executive
For pharma, diagnosing what ails or strengthens performance in this critical corporate discipline may help reshape business prognosis.
May 09, 2017
Peter Young offers a summary of the strategic issues facing the biopharma industry, reviews recent stock market, M&A and financing activity, and looks at the implications for senior management.
lorem ipsum